NCT05335018View on ClinicalTrials.gov

GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

May 30, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2026

Conditions
Relapsed/refractory Diffuse Large B Cell Lymphoma
Interventions
DRUG

Glofitamab, Poseltinib, Lenalidomide

"Glofitamab: Increase from 2.5mg for 8days in 1 cycle to 10mg for 15days. 2cycles 1day 30mg, 30 mg on the 1st day of every week thereafter. Poseltinib: 40mg/day bid orally, administered daily from the 1st to the 21st of every week.~Lenalidomide: 20mg/day bid orally, administered daily from the 1st to the 14st of every week."

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER